Navigation Links
Cardiome To Release 2008 First Quarter Results
Date:5/12/2008

bel safety study evaluating recent-onset AF patients, called ACT 4, has completed.

Vernakalant (oral) is being investigated as a chronic-use oral drug for the maintenance of normal heart rhythm following termination of AF. Cardiome announced positive results from a Phase 2a pilot study for vernakalant (oral) in September 2006. A Phase 2b study for vernakalant (oral) is ongoing.

In April 2007 Cardiome acquired exclusive worldwide rights for GED-aPC for all indications. Cardiome intends to initially develop GED-aPC in cardiogenic shock, a life-threatening form of acute circulatory failure due to cardiac dysfunction, which is a leading cause of death for patients hospitalized following a heart attack.

Cardiome is traded on the Toronto Stock Exchange (COM) and the NASDAQ National Market (CRME).

Forward-Looking Statement Disclaimer

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments expressed or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospect
'/>"/>

SOURCE Cardiome Pharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Cardiome To Release 2007 Results
2. Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor
3. Cardiome And Astellas Announce Regulatory Update
4. Cardiome to Hold Investor Update Call
5. Cardiome Updates Guidance
6. Cardiome Initiates Phase 1 Study for GED-aPC
7. Cardiome To Release Third Quarter Results
8. Cardiome to Present at CIBC Conference
9. Cardiome to Present at ThinkEquity Conference
10. Cardiome to Present at Bear Stearns Conference
11. Dynatronics to Release Third Quarter Results Wednesday, May 14, 2008; Conference Call Set for 2:30 p.m. ET
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 2014 UWDress.com, an internationally famous designer ... unveiled its fashionable assortment of fall bridesmaid dresses ... and old customers, the company is now providing big ... company’s discounted fall bridesmaid outfits are offered in many ... collection are priced less than $190. UWDress.com’s kind officials ...
(Date:8/28/2014)... these particular arguments against the policy, put forward by ... the first country in the world to introduce standardised ... Ireland, and the UK are currently considering similar legislation. ... policy would deter people from buying their tobacco from ... of cheap products sourced from Asia, and increase the ...
(Date:8/28/2014)... Recently, iFitDress.com, the distinguished wedding dress manufacturer and retailer, ... dresses . Included in the new range are hundreds ... are provided at deeply discounted prices, from 22 to ... and reliable delivery service. All clients from around the ... time. As is commonly noted, international customers have different ...
(Date:8/28/2014)... of women who are given information about the chance ... not fully understand the risks involved, according to research ... , today (Friday). , In a survey of around ... London (UCL) found that 64 per cent felt they ... chance that screening will pick up cancers that would ...
(Date:8/28/2014)... 2014 Blood's Thicker Than Water is based ... family ties in the heart of the city. Raymond E. ... story about how disrespect caused two families to collide with ... , The Yayo Boyz and the M.O.B. Boyz clash in ... local onlookers in a silent terror. "Guerrilla," AKA "Real," runs ...
Breaking Medicine News(10 mins):Health News:Fashionable Fall Bridesmaid Dresses From UWDress.com 2Health News:Plain cigarette packs don't hurt small retailers or boost trade in illicit tobacco 2Health News:New Selection of Chic Bridesmaid Dresses Available at iFitDress.com 2Health News:Some women still don't underststand 'overdiagnosis' risk in breast screening 2Health News:Raymond E. Blake Releases Blood's Thicker Than Water, Based on a True Story 2
... (June 24, 2010) The nerve cell-damaging plaque that ... builds up in the retinas of the eyes ... prospect that noninvasive optical imaging of the eyes could ... disease, according to new research. Scientists discovered characteristic ...
... of large sessile colorectal polyps is increasingly used as ... its technical difficulty, the high risk of complications such ... malignancy. This research, lead by Dr. Sohn DK ... demonstrated the safety of endoscopic piecemeal resection (EPMR) for ...
... may increase the risk of severe asthma attacks among people ... Harvard Medical School, Harvard Pilgrim Health Care Institute and Brigham ... on the American Thoracic Society,s journal Web site ahead of ... and Critical Care Medicine . "We found that the ...
... School of Medicine has received a $5.3 million grant from ... four-year clinical trial to show the effects of weight loss ... co-existing medical conditions in overweight breast cancer survivors. ,This ... study that will examine the effect of weight loss on ...
... coping with stress succumb easily to substance use cravings, ... to behavioral researchers. "Cravings are a strong predictor of ... development, Penn State. "The goal of this study is ... person on a within-day basis. Because recovery must be ...
... A pair of University of California San Diego researchers ... and disorders, and Yang Xu, an immunologist have ... from the California Institute for Regenerative Medicine (CIRM). ... Immunology awards totaling $25 million that were approved at ...
Cached Medicine News:Health News:Hallmark Alzheimer's disease changes found in retinas of humans and imaged in live animals 2Health News:Hallmark Alzheimer's disease changes found in retinas of humans and imaged in live animals 3Health News:Moldy homes a serious risk for severe asthma attacks in some 2Health News:UC San Diego researcher awarded $5.3 million for breast cancer survivorship study 2Health News:Ignoring stress leads recovering addicts to more cravings 2Health News:UCSD researchers receive $2.5 million in new stem cell grants 2
(Date:8/28/2014)... Aug. 28, 2014 Pharmatech initiated enrollment ... into this game-changing method for matching cancer patients ... clinical trials target specific cancers, disease staging, and ... for the cancer, in the first place. The ... information may not be well known to the ...
(Date:8/28/2014)... -- In anticipation of the upcoming MEDevice San Diego ... first time. Industry Overview: Medtech & Life Sciences in ... of San Diego,s critical involvement in ... employment statistics to current venture capital investment trends, the infographic ... such a vital part of the global medical device industry. ...
(Date:8/28/2014)... 2014 Nonin Medical, Inc., the inventor of ... monitoring, today announced that the Food and Drug Administration ... pulse oximeter for use in the United ... a telemedicine hub or kiosk through a USB connector ... to adult patients. The Model 3231 received EU certification ...
Breaking Medicine Technology:Enrollment in Pharmatech's Revolutionary AccessPPM Program Launches 2New Infographic Published - Overview of Medtech & Life Sciences Industry in San Diego 2Nonin Medical Announces FDA Clearance of Nonin Model 3231 USB Pulse Oximeter 2
... PRO-DEX, INC. (Nasdaq: PDEX ) invites investors and ... fiscal 2012 first quarter financial results. (Logo:   ... be broadcast live over the internet on Wednesday, November 9, ... and may be accessed by visiting the Company,s website at ...
... VIEW, Calif., Nov. 3, 2011 VIVUS, Inc. (NASDAQ: ... were published in Obesity, the peer-reviewed journal of The ... the investigational drug Qnexa in 1,267 severely obese (BMI >/= 35 ... addition to average weight loss of 14.4% of initial body weight ...
Cached Medicine Technology:Pro-Dex, Inc. Announces Fiscal 2012 First Quarter Financial Results Conference Call and Webcast 2Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment 2Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment 3Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment 4Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment 5Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment 6
...
... monitor is designed to automatically measure and ... along with heart rate. It's a Blood ... treadmill, ergometer and pharmacological stress test environments. ... research environments., ,Tango excels where other ...
...
...
Medicine Products: